Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Raltegravir PK Distribution in HIV
NCT03174977Phase 1Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Apr 2018
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-raltegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of California, San Francisco. Primary endpoints: Number of patients with microdose 18F-Raltegravir-related adverse events and Whole-body distribution of radiolabeled 18F-Raltegravir. Started Apr 2018; status: recruiting.
02
Drugs
18F-raltegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03174977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174977.